UNLABELLED: With the dismal prognosis for malignant glioma patients, survival predictions become key elements in patient management. This study compares the value of 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) PET and MRI for early outcome predictions in patients with recurrent malignant glioma on bevacizumab therapy. METHODS: Thirty patients treated with bevacizumab combination therapy underwent (18)F-FLT PET immediately before and at 2 and 6 wk after the start of treatment. A metabolic treatment response was defined as a decrease of equal to or greater than 25% in tumor (18)F-FLT uptake (standardized uptake values) from baseline using receiver-operating-characteristic analysis. MRI treatment response was assessed at 6 wk according to the Response Assessment in Neurooncology criteria. (18)F-FLT responses at different times were compared with MRI response and correlated with progression-free survival and overall survival using Kaplan-Meier analysis. Metabolic response based on (18)F-FLT was further compared with other outcome predictors using Cox regression analysis. RESULTS: Early and late changes in tumor (18)F-FLT uptake were more predictive of overall survival than MRI criteria (P < 0.001 and P = 0.01, respectively). (18)F-FLT uptake changes were also predictive of progression-free survival (P < 0.001). The median overall survival for responders was 3.3 times longer than for nonresponders based on (18)F-FLT PET criteria (12.5 vs. 3.8 mo, P < 0.001) but only 1.4 times longer using MRI assessment (12.9 vs. 9.0 mo, P = 0.05). On the basis of the 6-wk (18)F-FLT PET response, there were 16 responders (53%) and 14 nonresponders (47%), whereas MRI identified 9 responders (7 partial response, 2 complete response, 31%) and 20 nonresponders (13 stable disease, 7 progressive disease, 69%). In 7 of the 8 discrepant cases between MRI and PET, (18)F-FLT PET was able to demonstrate response earlier than MRI. Among various outcome predictors, multivariate analysis identified (18)F-FLT PET changes at 6 wk as the strongest independent survival predictor (P < 0.001; hazard ratio, 10.051). CONCLUSION: Changes in tumor (18)F-FLT uptake were highly predictive of progression-free and overall survival in patients with recurrent malignant glioma on bevacizumab therapy. (18)F-FLT PET seems to be more predictive than MRI for early treatment response.
UNLABELLED: With the dismal prognosis for malignant gliomapatients, survival predictions become key elements in patient management. This study compares the value of 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) PET and MRI for early outcome predictions in patients with recurrent malignant glioma on bevacizumab therapy. METHODS: Thirty patients treated with bevacizumab combination therapy underwent (18)F-FLT PET immediately before and at 2 and 6 wk after the start of treatment. A metabolic treatment response was defined as a decrease of equal to or greater than 25% in tumor (18)F-FLT uptake (standardized uptake values) from baseline using receiver-operating-characteristic analysis. MRI treatment response was assessed at 6 wk according to the Response Assessment in Neurooncology criteria. (18)F-FLT responses at different times were compared with MRI response and correlated with progression-free survival and overall survival using Kaplan-Meier analysis. Metabolic response based on (18)F-FLT was further compared with other outcome predictors using Cox regression analysis. RESULTS: Early and late changes in tumor (18)F-FLT uptake were more predictive of overall survival than MRI criteria (P < 0.001 and P = 0.01, respectively). (18)F-FLT uptake changes were also predictive of progression-free survival (P < 0.001). The median overall survival for responders was 3.3 times longer than for nonresponders based on (18)F-FLT PET criteria (12.5 vs. 3.8 mo, P < 0.001) but only 1.4 times longer using MRI assessment (12.9 vs. 9.0 mo, P = 0.05). On the basis of the 6-wk (18)F-FLT PET response, there were 16 responders (53%) and 14 nonresponders (47%), whereas MRI identified 9 responders (7 partial response, 2 complete response, 31%) and 20 nonresponders (13 stable disease, 7 progressive disease, 69%). In 7 of the 8 discrepant cases between MRI and PET, (18)F-FLT PET was able to demonstrate response earlier than MRI. Among various outcome predictors, multivariate analysis identified (18)F-FLT PET changes at 6 wk as the strongest independent survival predictor (P < 0.001; hazard ratio, 10.051). CONCLUSION: Changes in tumor (18)F-FLT uptake were highly predictive of progression-free and overall survival in patients with recurrent malignant glioma on bevacizumab therapy. (18)F-FLT PET seems to be more predictive than MRI for early treatment response.
Authors: Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang Journal: J Clin Oncol Date: 2010-03-15 Impact factor: 44.544
Authors: Christiaan Schiepers; Magnus Dahlbom; Wei Chen; Timothy Cloughesy; Johannes Czernin; Michael E Phelps; Sung-Cheng Huang Journal: J Nucl Med Date: 2010-04-15 Impact factor: 10.057
Authors: E T Wong; K R Hess; M J Gleason; K A Jaeckle; A P Kyritsis; M D Prados; V A Levin; W K Yung Journal: J Clin Oncol Date: 1999-08 Impact factor: 44.544
Authors: Benjamin M Ellingson; Timothy F Cloughesy; Albert Lai; Phioanh L Nghiemphu; Paul S Mischel; Whitney B Pope Journal: Neuro Oncol Date: 2011-02-15 Impact factor: 12.300
Authors: Ruediger E Port; Lisa J Bernstein; Daniel P Barboriak; Lu Xu; Timothy P L Roberts; Nicholas van Bruggen Journal: Magn Reson Med Date: 2010-08 Impact factor: 4.668
Authors: Norbert Galldiks; Lutz W Kracht; Lothar Burghaus; Roland T Ullrich; Heiko Backes; Anna Brunn; Wolf-Dieter Heiss; Andreas H Jacobs Journal: Mol Imaging Date: 2010-02 Impact factor: 4.488
Authors: Johannes Schwarzenberg; Johannes Czernin; Timothy F Cloughesy; Benjamin M Ellingson; Whitney B Pope; Tristan Grogan; David Elashoff; Cheri Geist; Daniel H S Silverman; Michael E Phelps; Wei Chen Journal: Clin Cancer Res Date: 2014-03-31 Impact factor: 12.531
Authors: Talia C Oughourlian; Jingwen Yao; Jacob Schlossman; Catalina Raymond; Matthew Ji; Hiroyuki Tatekawa; Noriko Salamon; Whitney B Pope; Johannes Czernin; Phioanh L Nghiemphu; Albert Lai; Timothy F Cloughesy; Benjamin M Ellingson Journal: J Neurooncol Date: 2020-01-24 Impact factor: 4.130
Authors: Viola Walther; Crispin T Hiley; Darryl Shibata; Charles Swanton; Paul E Turner; Carlo C Maley Journal: Nat Rev Clin Oncol Date: 2015-02-17 Impact factor: 66.675
Authors: Shehzahdi S Moonshi; Romain Bejot; Zeenat Atcha; Vimalan Vijayaragavan; Kishore K Bhakoo; Julian L Goggi Journal: Am J Nucl Med Mol Imaging Date: 2013-09-19
Authors: Lance T Hall; Benjamin Titz; H Ian Robins; Bryan P Bednarz; Scott B Perlman; Jamey P Weichert; John S Kuo Journal: Am J Nucl Med Mol Imaging Date: 2017-09-01
Authors: Kevin Leu; Whitney B Pope; Timothy F Cloughesy; Albert Lai; Phioanh L Nghiemphu; Wei Chen; Linda M Liau; Benjamin M Ellingson Journal: CNS Oncol Date: 2013-01